Taci fusion protein and use thereof
By developing the TACI fusion protein, which combines BAFF and APRIL with MASP3 or MASP2, multi-target regulation of the complement system and B cell activation pathways is achieved, solving the problem of limited efficacy in treating autoimmune diseases in existing technologies and realizing more comprehensive disease control.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- STAIDSON (BEIJING) BIOPHARMACEUTICALS CO LTD
- Filing Date
- 2025-12-09
- Publication Date
- 2026-06-18
AI Technical Summary
Existing technologies for treating autoimmune diseases typically target only a single target or signaling pathway, resulting in limited therapeutic effects and an inability to comprehensively regulate the activation of multiple related signaling pathways.
Develop a TACI fusion protein containing the extracellular domain of TACI or a variant thereof, capable of binding BAFF and APRIL, and specifically binding the antigen-binding domain of MASP3 or MASP2, to achieve multi-target regulation by inhibiting the complement system and B cell activation pathways.
It effectively inhibits complement activation and excessive B cell activation, reduces the production of autoantibodies, lowers the symptoms and inflammatory response of autoimmune diseases, and provides a more comprehensive therapeutic effect.
Smart Images
Figure 1 Figure 2